ReviewUpdates in surgery2016
Pancreatic cancer and liver metastases: state of the art.
Review in Updates in surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER-based analysis of 15,836 cases.Cancer medicine · 2021Trial
- The Value of Primary Tumor Resection in Patients with Liver Metastases: A 10-Year Outcome.Annals of surgical oncology · 2025Article
- Review
- Resection of isolated liver oligometastatic disease in pancreatic ductal adenocarcinoma: Is there a survival benefit? A systematic review.World journal of gastrointestinal surgery · 2023Article
- Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study.Journal of personalized medicine · 2023Article
- Article
- Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX.Visceral medicine · 2021Article
- Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma.Pharmaceutics · 2021Review
- Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis.Nature cell biology · 2020Article
- Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis.British journal of cancer · 2020Article
- Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.British journal of cancer · 2020Article
- Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects.Therapeutic advances in medical oncology · 2020Article
- Article
- Article
- Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues.Surgery today · 2019Review
- Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes.Genes & cancer · 2018Article
- Mean platelet volume predicts survival in pancreatic cancer patients with synchronous liver metastases.Scientific reports · 2018Article
- Liver resection for non-colorectal metastases.European surgery : ACA : Acta chirurgica Austriaca · 2018Article
- Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer.Oncotarget · 2017Article
- Challenges in pancreatic adenocarcinoma surgery - National survey and current practice guidelines.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. In the detection of hepatic metastases, the current standard is palliative chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nab-paclitaxel with gemcitabine. Once hepatic metastases are diagnosed, the guidelines do not recommend resection of the primary tumor. Recent findings suggest that some patients with non-resectable diseases initially have survival rates as good as those with initially resectable disease when they are able to undergo surgical resection. Synchronous resection of both the primary tumour as well as the liver metastases may be beneficial and improves the outcome.
Indexed as
Identifiers
27832445What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.